Oral semaglutide showed superior reductions in blood sugar vs Jardiance(R) and non-inferior blood sugar reductions vs Victoza(R) in adults with type 2 diabetes at 26 weeks

Food and Healthcare Press Releases Monday June 10, 2019 08:20
SAN FRANCISCO--10 Jun--PRNewswire/InfoQuest
Abstracts 54-OR and 55-OR
Secondary data at 52 weeks demonstrated statistically significant blood sugar reductions and statistically significant reduction of body weight vs both Jardiance(R) and Victoza(R)

Findings presented today from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance(R) (empagliflozin 25 mg) in PIONEER 2 and oral semaglutide 14 mg versus Victoza(R) (liraglutide 1.8 mg) in PIONEER 4 over 52 weeks in adults with type 2 diabetes. Data from both trials were presented at the American Diabetes Association (ADA) 79thScientific Sessions. Oral semaglutide is an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue in a pill.

In PIONEER 2, oral semaglutide 14 mg demonstrated a superior HbA1c reduction of 1.3% compared to a 0.9% reduction with empagliflozin 25 mg for the primary endpoint at 26 weeks (p<0.0001) and a statistically significant reduction in HbA1c for the secondary endpoint at 52 weeks. Furthermore, for the secondary endpoint, the reduction in body weight with oral semaglutide was similar to empagliflozin with no statistical differences at both 26 and 52 weeks (3.8 kg for oral semaglutide at both 26 and 52 weeks, 3.7 kg and 3.6 kg for empagliflozin, respectively).

In PIONEER 4, for the primary endpoint at 26 weeks, oral semaglutide 14 mg demonstrated a non-inferior reduction in HbA1c vs Victoza(R) (1.2% vs 1.1%, respectively) and a superior reduction vs placebo (1.2% vs 0.2%, respectively) in adults with type 2 diabetes inadequately controlled on metformin, with or without a sodium-glucose co-transporter-2 (SGLT-2) inhibitor. For the secondary endpoint at 52 weeks, oral semaglutide demonstrated statistically significant reductions in HbA1c vs both Victoza(R) (1.2% vs 0.9%, respectively) and placebo (1.2% vs 0.2%, respectively). For the secondary endpoint of change in body weight, oral semaglutide demonstrated superior reductions compared to both Victoza(R) and placebo at 26 weeks (4.4 kg for oral semaglutide, 3.1 kg for Victoza(R) and 0.5 kg for placebo) and statistically significant reductions compared to both at 52 weeks (4.3 kg for oral semaglutide, 3.0 kg for Victoza(R) and 1.0 kg for placebo).

In PIONEER 2, the most common adverse event for oral semaglutide was nausea, which diminished over time, affecting 20% of people treated with oral semaglutide. The nausea rate for empagliflozin was 2%. The proportion of people who discontinued treatment due to adverse events was 11% for those treated with oral semaglutide compared to 4% for those treated with empagliflozin.

In PIONEER 4, the most common adverse event for oral semaglutide was nausea, which diminished over time, affecting 20% of people treated with oral semaglutide. For people treated with Victoza(R) and placebo, 18% and 4%, respectively, experienced nausea. The proportion of people who discontinued treatment due to adverse events was 11% for those treated with oral semaglutide compared to 9% with Victoza(R) and 4% with placebo.

These results are based on the primary statistical approach known as the treatment policy (TPol) estimand, which was used to assess the effects of oral semaglutide regardless of discontinuation of trial product and/or use of rescue medication.

"Despite their proven safety and efficacy, GLP-1 receptor agonists are underutilised in clinical care" said Ildiko Lingvay, PIONEER 2 and 4 investigator and professor at the Departments of Internal Medicine and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas. "As a treating physician, I'm encouraged by these findings and the potential of investigational oral semaglutide to be the first oral GLP-1 receptor agonist available as a new treatment option for people living with type 2 diabetes."

The following results from PIONEER 2 and 4 were also presented today at the ADA and are based on the secondary statistical approach. The secondary statistical approach is known as the trial product estimand and is used to assess the effect of oral semaglutide, assuming all patients remained on trial product and did not use rescue medication:

PIONEER 2:
  • Oral semaglutide demonstrated statistically significant reductions in HbA1c vs empagliflozin at 26 weeks (1.4% vs 0.9%, respectively) and at 52 weeks (1.3% vs 0.8%, respectively).
  • Oral semaglutide demonstrated a body weight reduction of 4.2 kg vs 3.8 kg with empagliflozin at 26 weeks and a statistically significant reduction of 4.7 kg vs 3.8 kg at 52 weeks.
PIONEER 4:
  • Oral semaglutide demonstrated statistically significant reductions in HbA1c vs Victoza(R) and vs placebo at both 26 and 52 weeks (1.3% for oral semaglutide, 1.1% for Victoza(R) and 0.1% for placebo at 26 weeks; 1.2% for oral semaglutide, 0.9% for Victoza(R)and a 0.2% increase for placebo at 52 weeks).
  • Oral semaglutide demonstrated statistically significant reductions in body weight vs Victoza(R) and vs placebo at both 26 and 52 weeks (4.7 kg for oral semaglutide, 3.2 kg for Victoza(R) and 0.7 kg for placebo at 26 weeks; 5.0 kg for oral semaglutide, 3.1 kg for Victoza(R) and 1.2 kg for placebo at 52 weeks).
About PIONEER 2, PIONEER 4 and the PIONEER clinical trial programme

PIONEER 2 was a 52-week, randomised, open-label, active-controlled, parallel-group, multicentre, multinational trial with two arms comparing the efficacy and safety of oral semaglutide 14 mg with empagliflozin 25 mg in people with type 2 diabetes, inadequately controlled on metformin. 822 people were enrolled in PIONEER 2 and randomised 1:1 to receive either oral semaglutide or empagliflozin once daily. The primary endpoint was change in HbA1c from baseline to week 26 and the confirmatory secondary endpoint was change in body weight from baseline to week 26. Additional key secondary endpoints included change in HbA1c and body weight from baseline to week 52.

PIONEER 4 was a 52-week, randomised, double-blinded, double-dummy, active- and placebo-controlled, parallel-group, multicentre, multinational trial with three arms comparing the efficacy and safety of oral semaglutide 14 mg compared to Victoza(R) (1.8 mg liraglutide) or placebo in people with type 2 diabetes, inadequately controlled on metformin with or without an SGLT-2 inhibitor. PIONEER 4 randomised 711 people in a 2:2:1 manner to receive either oral semaglutide, Victoza(R) or placebo once-daily. The primary endpoint was change from baseline to week 26 in HbA1c. Key secondary endpoints included change in HbA1c and body weight from baseline to week 52.

The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme that enrolled 9,543 people with type 2 diabetes across 10 clinical trials.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com,Facebook, Twitter, LinkedIn, YouTube.

References

1. Montanya E, Rosenstock J, Canani LH, et al. Oral semaglutide vs empagliflozin added-on to metformin monotherapy in uncontrolled type 2 diabetes: PIONEER 2. Abstract number 54-OR, American Diabetes Association 79th Scientific Session, San Francisco, US; 7-11 June 2019

2. Pratley RE, Amod A, Hoff ST, et al. Oral Semaglutide vs Liraglutide and Placebo in T2D: PIONEER 4. Abstract number 55-OR, American Diabetes Association 79th Scientific Session, San Francisco, US; 7-11 June 2019

Further information
Media:
Katrine Sperling
+45 4442 6718
krsp@novonordisk.com
Michael Bachner (US)
+1 609 664 7308
mzyb@novonordisk.com
Investors:
Peter Hugreffe Ankersen
+45 3075 9085
phak@novonordisk.com
Valdemar Borum Svarrer
+45 3079 0301
jvls@novonordisk.com
Ann Sondermolle Rendbaek
+45 3075 2253
arnd@novonordisk.com
Kristoffer Due Berg (US)
+1 609 235 2989
krdb@novonordisk.com

Latest Press Release

Biotech Conagen Acquires Production Platform of Therapeutic Proteins

Conagen, a vertically integrated synthetic biology company located in Boston's biotech corridor, announced today that it has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins. The acquisition includes...

Pneuma Respiratory, Inc. Announces New Chairman of the Board

Pneuma Respiratory, Inc. announced that Board member Jay Morgan has assumed the position of Chairman of the Board. Pneuma's previous Chairman, Walt Robb, will remain a member of the Board of Directors. Jay Morgan served as VP Global Innovation and...

Global market of dietary supplement is welcoming a rising star GLYMATE

Glymate(TM), a newly founded nutraceutical company in Southern California. Its proprietary sugar balance dietary supplement was officially announced in the United States in June 2019, marking the official launch of the global marketing of this product,...

Xinhua Silk Road: Tasly remains China#s 2019 National Tech Innovation Demonstration Enterprise

Tasly Holding Group, one of China's leading pharmaceuticals companies, has recently passed through the country's review of National Technology Innovation Demonstration Enterprise in 2019, thanks to its continuous innovations made in the recent...

SweeGen#s non-GMO Reb M Stevia Leaf Sweetener Approved in Singapore

SweeGen, Inc., a nature-based sweetener company, announced the Singapore Food Agency has added SweeGen's Reb M Stevia Leaf Sweetener to the list of permitted food additives. SweeGen's Reb M is a non-caloric stevia sweetener that provides sweetness with...

Related Topics